Emergence of dysfunctional neutrophils with a defect in arginase-1 release in severe COVID-19

A Dwivedi, AU Mhaonaigh, M Carroll, B Khosravi… - JCI …, 2024 - pmc.ncbi.nlm.nih.gov
Neutrophilia occurs in patients infected with SARS-CoV-2 (COVID-19) and is predictive of
poor outcomes. Here, we link heterogenous neutrophil populations to disease severity in …

Data quality and patient characteristics in European ANCA-associated vasculitis registries: data retrieval by federated querying

K Gisslander, M Rutherford, L Aslett, N Basu… - Annals of the Rheumatic …, 2024 - Elsevier
Objectives This study aims to describe the data structure and harmonisation process,
explore data quality and define characteristics, treatment, and outcomes of patients across …

Effect of immunosuppression on the immune response to SARS-CoV-2 infection and vaccination

EJ Leacy, JW Teh, AM O'Rourke, G Brady… - International Journal of …, 2024 - mdpi.com
Immunosuppressive treatment in patients with rheumatic diseases can maintain disease
remission but also increase risk of infection. Their response to severe acute respiratory …

Computable phenotype for real-world, data-driven retrospective identification of relapse in ANCA-associated vasculitis

J Scott, A White, C Walsh, L Aslett, MA Rutherford… - RMD open, 2024 - rmdopen.bmj.com
Objective ANCA-associated vasculitis (AAV) is a relapsing-remitting disease, resulting in
incremental tissue injury. The gold-standard relapse definition (Birmingham Vasculitis …

Autoantibodies towards HFE and SYT5 in anti-neutrophil cytoplasm antibody-associated vasculitis relapse

S Bayati, J Nazeer, J Ng, AM George, M Hayes… - …, 2024 - academic.oup.com
Objective Identification of those at high and low risk of disease relapse is a major unmet
need in the management of patients with ANCA-associated vasculitis (AAV). Precise …